lisocabtagene maraleuce (BREYANZI)

Indications

• treatment of adults with relapsed or refractory large B-cell lymphoma after multiple lines of systemic therapy, high-grade B-cell lymphoma, & follicular lymphoma grade 3B

Dosage

• 50-110 106 CAR-positive viable T-cells (consisting of CD8 & CD4 components)

* cell suspension for infusion, 70000000 CELLS/ML

Adverse effects

• most common:
  • fatigue, cytokine release syndrome, musculoskeletal pain, nausea, headache, encephalopathy, infections, anorexia, diarrhea, hypotension, tachycardia, dizziness, cough, constipation, abdominal pain, vomiting, edema

* boxed warning

• cytokine release storm
• neurotoxicity

Mechanism of action

• CD19-directed genetically modified autologous T-cell immunotherapy

More general terms

• chimeric antigen-receptor T-cell therapy